Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
This retrospective study suggests that obinutuzumab is an effective treatment option for patients with primary membranous nephropathy refractory to GC + CTX, CNI and rituximab regimens.
Authors
- Qionghong Xie (ORCID: https://orcid.org/0000-0002-6189-2909)
- Wenqian Zhao (ORCID: https://orcid.org/0000-0001-9501-9254)
- Chuan‐Ming Hao (ORCID: https://orcid.org/0000-0002-4307-0987)
- Yifeng Wang (ORCID: https://orcid.org/0000-0001-5708-0951)
- Mingxin Li (ORCID: https://orcid.org/0000-0001-8252-2758)
- Mingyue Xu (ORCID: https://orcid.org/0009-0003-7793-344X)
- Ruiying Chen (ORCID: https://orcid.org/0000-0003-2556-7604)
- MS Yuejin Wu
Institutions
- Fudan University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1093/ndt/gfae230
- Citations
- 21
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 7.12
Funders
- National Natural Science Foundation of China
- Fudan University
- Huashan Hospital